Appeal No. 2007-0083
Application No. 10/174,574
ID NO:31, which encodes a polypeptide referred to as “PRO270,” which has
the amino acid sequence shown in SEQ ID NO:32. Page 8 and Figure 32.
The encoded amino acid sequence is disclosed to include a signal sequence,
transmembrane domain, sites for various post-translational modifications,
and a “Myb DNA-binding domain repeat signature 1.” Figure 32.
The present specification does not further characterize the amino acid
sequence of SEQ ID NO:32. However, the present application claims
priority as follows:
This application is a continuation of . . . a continuation of . . . a
continuation-in-part of . . . US Application 09/380139 filed
8/25/1999, now abandoned, which is the National Stage filed
under 35 USC §371 of PCT Application PCT/US98/19330 filed
9/16/1998, which claims priority under 35 USC § 119 to US
provisional application 60/063121 filed 10/24/1997.
Preliminary Amendment filed Sept. 18, 2002, pages 1-2.
PCT application US98/19330 was published as WO 99/14328 on
March 25, 1999. Thus, the contents of that application were known to those
of ordinary skill in the art as of that date. WO 99/14328 characterizes
PRO270 as follows:
Thioredoxins [a]ffect reduction-oxidation (redox) state. Many
diseases are potentially related to redox state and reactive
oxygen species may play a role in many important biological
processes. The transcription factors, NF-kappa-B and AP-1, are
regulated by redox state and are known to affect the expression
of a large variety of genes thought to be involved in the
pathogenesis of AIDS, cancer, atherosclerosis and diabetic
complications. Such proteins may also play a role in cellular
antioxidant defense, and in pathological conditions involving
oxidative stress such as stroke and inflammation in addition to
having a role in apoptosis. Therefore, thioredoxins, and
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: September 9, 2013